Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 367

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Protection against malaria at 1 year and immune correlates following PfSPZ vaccination

Open access
Ishizuka, Andrew S, Lyke, Kirsten E, DeZure, Adam, Berry, Andrea A, Richie, Thomas L, Mendoza, Floreliz H, Enama, Mary E, Gordon, Ingelise J, Chang, Lee-Jah, Sarwar, Uzma N, Zephir, Kathryn L, Holman, LaSonji A, James, Eric R, Billingsley, Peter F, Gunasekera, Anusha, Chakravarty, Sumana, Manoj, Anita, Li, MingLin, Ruben, Adam J, Li, Tao, Eappen, Abraham G, Stafford, Richard E, K C, Natasha, Murshedkar, Tooba, DeCederfelt, Hope, Plummer, Sarah H, Hendel, Cynthia S, Novik, Laura, Costner, Pamela J M, Saunders, Jamie G, Laurens, Matthew B, Plowe, Christopher V, Flynn, Barbara, Whalen, William R, Todd, J P, Noor, Jay, Rao, Srinivas, Sierra-Davidson, Kailan, Lynn, Geoffrey M, Epstein, Judith E, Kemp, Margaret A, Fahle, Gary A, Mikolajczak, Sebastian A, Fishbaugher, Matthew, Sack, Brandon K, Kappe, Stefan H I, Davidson, Silas A, Garver, Lindsey S, Björkström, Niklas K, Nason, Martha C, Graham, Barney S, Roederer, Mario, Sim, B Kim Lee, Hoffman, Stephen L, Ledgerwood, Julie E, Seder, Robert A·2016·Nature Medicine
DOI 10.1038/nm.4110
Open this paper in CoChat — free account

Abstract

An attenuated Plasmodium falciparum (Pf) sporozoite (SPZ) vaccine, PfSPZ Vaccine, is highly protective against controlled human malaria infection (CHMI) 3 weeks after immunization, but the durability of protection is unknown. We assessed how vaccine dosage, regimen, and route of administration affected durable protection in malaria-naive adults. After four intravenous immunizations with 2.7 × 105 PfSPZ, 6/11 (55%) vaccinated subjects remained without parasitemia following CHMI 21 weeks after immunization. Five non-parasitemic subjects from this dosage group underwent repeat CHMI at 59 weeks, and none developed parasitemia. Although Pf-specific serum antibody levels correlated with protection up to 21–25 weeks after immunization, antibody levels waned substantially by 59 weeks. Pf-specific T cell responses also declined in blood by 59 weeks. To determine whether T cell responses in blood reflected responses in liver, we vaccinated nonhuman primates with PfSPZ Vaccine. Pf-specific interferon-γ-producing CD8 T cells were present at ∼100-fold higher frequencies in liver than in blood. Our findings suggest that PfSPZ Vaccine conferred durable protection to malaria through long-lived tissue-resident T cells and that administration of higher doses may further enhance protection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nm.4110

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 367

Metadata

Authors
Ishizuka, A. S., Lyke, K. E., DeZure, A., Berry, A. A., Richie, T. L., Mendoza, F. H., Enama, M. E., Gordon, I. J., Chang, L.-J., Sarwar, U. N., Zephir, K. L., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., Chakravarty, S., Manoj, A., Li, M., Ruben, A. J., Li, T., Eappen, A. G., Stafford, R. E., K C, N., Murshedkar, T., DeCederfelt, H., Plummer, S. H., Hendel, C. S., Novik, L., Costner, P. J. M., Saunders, J. G., Laurens, M. B., Plowe, C. V., Flynn, B., Whalen, W. R., Todd, J. P., Noor, J., Rao, S., Sierra-Davidson, K., Lynn, G. M., Epstein, J. E., Kemp, M. A., Fahle, G. A., Mikolajczak, S. A., Fishbaugher, M., Sack, B. K., Kappe, S. H. I., Davidson, S. A., Garver, L. S., Björkström, N. K., Nason, M. C., Graham, B. S., Roederer, M., Sim, B. K. L., Hoffman, S. L., Ledgerwood, J. E., & Seder, R. A.
Venue
Nature Medicine
Publisher
Springer Science and Business Media LLC
Published
2016-05-09
Volume
22
Issue
6
Pages
614-623
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
DOI
10.1038/nm.4110
OpenAlex
W2346928357
Cited by
367
References
44
FWCI
46.55
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.